[CAS NO. 837-52-5] 7-Chloro-4-(piperazin-1-yl)quinoline

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [837-52-5]

Catalog

HY-W020111

Brand

MCE

CAS

837-52-5

DESCRIPTION [837-52-5]

Overview

MDL	MFCD01476123
Molecular Weight	247.72
Molecular Formula	C13H14ClN3
SMILES	ClC1=CC2=C(C(N3CCNCC3)=CC=N2)C=C1

For research use only. We do not sell to patients.

Summary

7-Chloro-4-(piperazin-1-yl)quinolone is an important scaffold in medicinal chemistry. 7-Chloro-4-(piperazin-1-yl)quinolone is a potent sirtuin inhibitor and also inhibits the serotonin uptake ( IC ₅₀ of 50 μM). 7-Chloro-4-(piperazin-1-yl)quinolone exhibits antimalarial activity on D10 and K1 strains of P. falciparum with IC ₅₀ s of 1.18 μM and 0.97 μM, respectively ^[1] .

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 16.67 mg/mL ( 67.29 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.0368 mL	20.1841 mL	40.3682 mL
5 mM	0.8074 mL	4.0368 mL	8.0736 mL
10 mM	0.4037 mL	2.0184 mL	4.0368 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 1.67 mg/mL (6.74 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 1.67 mg/mL (6.74 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 1.67 mg/mL (6.74 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Aida M Abd El-Sattar El-Azzouny, et al. Structural and biological survey of 7-chloro-4-(piperazin-1-yl)quinoline and its derivatives. Drug Dev Res. 2020 Nov;81(7):786-802.